Private Adimab Breaks $1 Billion Valuation, Offers VCs Liquidity Through $100 Million Secondary
This article was originally published in Start Up
A secondary offering by the privately held antibody discovery play has valued the company at more than a billion dollars and allowed its venture investors to cash in some or all of their positions. Meanwhile, Adimab continues to announce new partnerships including a monoclonal and bispecific antibody discovery pact with Sanofi.
Register for our free email digests: